Status:
COMPLETED
Sildenafil for Treatment of Choroidal Ischemia
Lead Sponsor:
Columbia University
Conditions:
Choroidal Ischemia
Vitelliform Macular Dystrophy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform ...
Detailed Description
Age-Related Macular Degeneration (AMD) is a sight-threatening visual disturbance that affects the macula in older ages. It is irreversible if the pigment epithelium is lost (dry AMD), but wet AMD can ...
Eligibility Criteria
Inclusion
- Diagnosis of retinal and choroidal degenerations (reticular or vitelliform AMD or vitelliform-type subretinal drusen) or hereditary or acquired retinal dystrophies (retinitis pigmentosa or central serous retinopathy)
Exclusion
- Diagnosis of heart disease requiring use of nitrates
- Inability to be examined monthly or bi-monthly
Key Trial Info
Start Date :
November 11 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 18 2020
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT04356716
Start Date
November 11 2014
End Date
February 18 2020
Last Update
July 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center, Edward Harkness Eye Institute
New York, New York, United States, 10032